MENU
Showcases Stock ranks Forex

Merck & Company (MRK)
99.72  -1.17 (-1.16%) 12-05 16:00
Open: 101.4 Pre. Close: 100.89
High: 102.09 Low: 99.19
Volume: 10,384,090 Market Cap: 250,617(M)
Stock Technical Analysis
Overall:     
Target: Six months: 123.62
One year: 144.39
Support: Support1: 91.11
Support2: 82.01
Resistance: Resistance1: 105.84
Resistance2: 123.62
Pivot: 99.42
Moving Averages: MA(5): 101.15
MA(20): 96.98
MA(100): 86.40
MA(250):
MACD: MACD(12,26): 3.79
Signal(12,26,9): 3.85
%K %D: %K(14,3): 66.77
%D(3): 71.96
RSI: RSI(14): 60.19
52-Week: High: 105.84
Low: 73.31
Change(%): 0.6
Average Vol(K): 3-Month: 13104
10-Days: 14808
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 102.287 - 102.868 102.868 - 103.499
Low: 97.58 - 98.22 98.22 - 98.915
Close: 98.513 - 99.626 99.626 - 100.834
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.

[ MRK ] has closed below upper band by 48.1%. Bollinger Bands are 68% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
Company profile
Stock chart
Stock News
Fri, 05 Dec 2025
Merck's Keytruda SC launch in Germany faces new hurdle as Halozyme scores preliminary injunction - Fierce Pharma

Fri, 05 Dec 2025
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis) - BioSpace

Fri, 05 Dec 2025
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results - NeurologyLive

Thu, 04 Dec 2025
Merck suffers a setback over its new Keytruda formulation in Germany - statnews.com

Thu, 04 Dec 2025
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case - The Wall Street Journal

Thu, 04 Dec 2025
Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - Seeking Alpha

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange: 
Sector: 
Industry: 
Shares Out. (M) 2480.00
Shares Float (M) 2480.00
% Held by Insiders 0.06
% Held by Institutions 80.30
Shares Short (K) 27630
Shares Short Prior Month (K) 26700
Stock Financials
EPS 7.560
Book Value (p.s.) 20.840
Profit Margin 29.63
Operating Margin 40.80
Return on Assets (ttm) 13.8
Return on Equity (ttm) 39.5
Qtrly Rev. Growth 3.7
Gross Profit (p.s.) 20.165
Sales Per Share 25.899
EBITDA (p.s.) 12.710
Qtrly Earnings Growth 87.00
Operating Cash Flow (M) 17060.00
Levered Free Cash Flow (M) 14530.00
Stock Valuation
PE Ratio 13.19
PEG Ratio
Price to Book value 4.79
Price to Sales 3.85
Price to Cash Flow 14.50
Stock Dividends
Dividend 0.810
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android